Sorafenib for Hepatocellular Carcinoma Recurrence After Liver Transplant Reply

被引：0
|
作者：
Invernizzi, Federica [1 ]
Iavarone, Massimo [1 ]
机构：
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, CRC AM & A Migliavacca Ctr Liver Dis, Milan, Italy
来源：
TRANSPLANTATION | 2020年 / 104卷 / 08期
关键词：
ORTHOTOPIC MODEL; COMBINATION; INHIBITORS; RAPAMYCIN;
D O I：
10.1097/TP.0000000000003229
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：E244 / E244
页数：1
相关论文
共 50 条
  • [1] Sorafenib for Hepatocellular Carcinoma Recurrence After Liver Transplant
    Mancuso, Andrea
    TRANSPLANTATION, 2020, 104 (08) : E243 - E243
  • [2] Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation
    Weinmann, Arndt
    Niederle, Ina Maria
    Koch, Sandra
    Hoppe-Lotichius, Maria
    Heise, Michael
    Dueber, Christoph
    Schuchmann, Marcus
    Otto, Gerd
    Galle, Peter Robert
    Woerns, Marcus-Alexander
    DIGESTIVE AND LIVER DISEASE, 2012, 44 (05) : 432 - 437
  • [3] EVEROLIMUS AND SORAFENIB FOR RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION
    De Simone, Paolo
    Pezzati, Daniele
    Lai, Quirino
    Ghinolfi, Davide
    Coletti, Laura
    Precisi, Arianna
    Leonardi, Giulia
    Carrai, Paola
    Filipponi, Franco
    TRANSPLANT INTERNATIONAL, 2013, 26 : 293 - 293
  • [4] Recurrence of Hepatocellular Carcinoma After Orthotopic Liver Transplant
    Bansal, Sourav
    Dommaraju, Sunil
    Thaker, Sarang
    Karimi, Saman
    Guzman, Grace
    Di Cocco, Pierpaolo
    Benedetti, Enrico
    Koppe, Sean
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S1991 - S1991
  • [5] SURVIVAL AND RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANT
    Mitlyng, B.
    Smith, C.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S227 - S227
  • [6] Sorafenib Prophylaxis Is Effective in Preventing Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients
    Saab, Sammy
    McTigue, Mike
    Finn, Richard
    Busuttil, Ronald W.
    LIVER TRANSPLANTATION, 2010, 16 (06) : S192 - S192
  • [7] Lenvatinib versus sorafenib for recurrence of hepatocellular carcinoma after liver transplantation
    Perera, S.
    Magyar, C. T. J.
    Rajendran, L.
    Li, Z.
    Almugbel, F. A.
    Feng, S.
    Choi, W. J.
    Aceituno, L.
    Selzner, N.
    Jaeckel, E.
    Falla-Rad, N.
    Knox, J. J.
    Chen, E. X.
    O'Kane, G. M.
    Sapisochin, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S82 - S83
  • [8] Nivolumab after sorafenib failure in liver recipients with hepatocellular carcinoma recurrence
    Kwon, J.
    Park, S.
    Yun, S. O.
    Yang, J.
    Lim, M.
    Rhu, J.
    Choi, G. -S.
    Kim, J. M.
    Joh, J. -W.
    TRANSPLANTATION, 2023, 107 (09) : 265 - 265
  • [9] Sorafenib Reduced Recurrence of Large Hepatocellular Carcinoma after Liver Transplantation
    Asham, Emad
    Boktour, Maha
    Mcfaden, Robert
    Monsour, Howard
    Gaber, Osama
    Ghobrial, R. Mark
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 88 - 88
  • [10] Sorafenib in Liver Transplant (LT) Recipients at High Risk of Hepatocellular Carcinoma (HCC) Recurrence
    Yan, W.
    Agrawal, N.
    Gadwale, G.
    Laurin, J.
    Satoskar, R.
    Manzanares, K.
    He, R.
    Johnson, L.
    Fishbein, T.
    Shetty, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 113 - 113
12345